Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2007
06/14/2007WO2007067537A1 Pyrrolopyridine kinase inhibiting compounds
06/14/2007WO2007067498A1 Estrogen cancer therapy
06/14/2007WO2007067444A1 Bicyclic compounds with kinase inhibitory activity
06/14/2007WO2007067048A1 Treatment of barrett's esophagus
06/14/2007WO2007066928A1 Use of the extract of caesalpinia sappan l. and compounds therefrom
06/14/2007WO2007066823A1 Antibody against connective tissue growth factor or composition containing the same
06/14/2007WO2007066781A1 Process for producing pharmaceutical composition containing drug-encapsulating polymer micelle using fluorine-containing organic solvent
06/14/2007WO2007066557A1 Phosphine transition metal complex, method for producing same and antitumor agent containing same
06/14/2007WO2007066423A1 Tumor antigen peptide derived from amacr
06/14/2007WO2007066181A2 Methods of preparing a vegf-r inhibitor
06/14/2007WO2007066106A1 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
06/14/2007WO2007066103A1 Pyrimidine derivatives as class i pi3k inhibitor
06/14/2007WO2007066102A1 Pyrimidine derivatives
06/14/2007WO2007066099A1 Pyrimidine derivatives
06/14/2007WO2007065940A1 Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones
06/14/2007WO2007065939A1 Substituted thiazole derivatives and their uses as tyrosine kinase inhibitors
06/14/2007WO2007065898A1 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
06/14/2007WO2007065869A1 Labelled docetaxel
06/14/2007WO2007065743A1 Compounds for use in treating abnormal cell proliferation, and methods of producing same
06/14/2007WO2007065690A1 Compositions and methods for therapy and diagnosis of cancer
06/14/2007WO2007065664A2 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
06/14/2007WO2007065518A1 Pyridiazinone derivatives for tumour treatment
06/14/2007WO2007065439A1 Method for generating dendritic cells employing decreased temperature
06/14/2007WO2007065376A1 Use of cortex prunus armeniaca l. and extracts thereof in manufacturing medicaments for treating cancerous pain
06/14/2007WO2007065375A1 Use of apricot bark and extracts thereof in manufacturing medicaments for treating cancer
06/14/2007WO2007050784A3 Fixed ratio drug combination treatments for solid tumors
06/14/2007WO2007044950A3 Crystalline forms of docetaxel and processes for their preparation
06/14/2007WO2007044560A3 Modulators of atp-binding cassette transporters
06/14/2007WO2007044407A3 Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
06/14/2007WO2007044050A3 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
06/14/2007WO2007034210A3 Deglycosylated anti-muc-1 antibodies and uses thereof
06/14/2007WO2007028047A3 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
06/14/2007WO2007024921A3 Combination therapies for inhibiting integrin-extracellular matrix interactions
06/14/2007WO2007021839A3 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
06/14/2007WO2007017212A3 Use of an active biological substance in abnormal cellular and viral membrane physiologies
06/14/2007WO2007015171A3 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
06/14/2007WO2007002525A3 Tomoregulin antibodies and uses thereof
06/14/2007WO2006123246A3 Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors
06/14/2007WO2006123183A3 Sulphone derivatives for treatment of cancer
06/14/2007WO2006120580A3 Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
06/14/2007WO2006117566A3 Botanical anticancer formulations
06/14/2007WO2006100213A8 Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor
06/14/2007WO2006085334A3 Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
06/14/2007WO2006048768A8 Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
06/14/2007US20070135523 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity
06/14/2007US20070135505 Aralkyl ester soft drugs
06/14/2007US20070135502 Heterocyclic compounds and methods of use
06/14/2007US20070135477 Benzimidazole derivatives and their use as protein kinases inhibitors
06/14/2007US20070135464 Antiinflammation agents
06/14/2007US20070135447 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
06/14/2007US20070135444 Treatment of neuroblastoma
06/14/2007US20070135433 Imidazole derivatives as raf kinase inhibitors
06/14/2007US20070135415 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
06/14/2007US20070135413 Treatment of glial tumors with glutamate antagonists
06/14/2007US20070135386 Novel Compounds and Compositions as Cathepsin Inhibitors
06/14/2007US20070135381 Derivatives of branch-chain lipophilic molecular and uses thereof
06/14/2007US20070135371 Antisense IAP nucleobase oligomers and uses thereof
06/14/2007US20070135366 evaluating the amount of cancer cells existing in pancreatic cells or tissues, by measuring the methylation frequency of Fibrillin2 gene or an index value having the correlation therewith, and comparing with a control; medical diagnosis
06/14/2007US20070135346 Prodrugs of CC-1065 analogs
06/14/2007US20070135344 Novel growth factor and a genetic sequence encoding same
06/14/2007US20070134744 Epothilone resistant cell lines
06/14/2007US20070134674 Method for the prognosis and/or diagnosis of a cancer
06/14/2007US20070134654 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
06/14/2007US20070134275 Medicaments for the immunotherapy of malignant tumors
06/14/2007US20070134250 Composition Comprising and Method of Using Angiopoietin-Like Protein 3 ANGPTL3
06/14/2007US20070134241 Humanized anti-CD3 specific antibodies
06/14/2007US20070134239 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
06/14/2007US20070134228 Immunoaffinity purification
06/14/2007US20070134183 Aminosulfonic acid compounds for promoting desquamation of the skin
06/14/2007US20070134153 Lipid-based drug delivery systems against parasitic infections
06/14/2007DE19936997B4 Verfahren zur Applikation von Photosensibilisatoren (PS) mittels Multiplikatoren in der photodymamischen Therapie A process for the application of photosensitizers (PS) by means of multipliers in the therapy photodymamischen
06/14/2007DE10297513B4 In vitro Herstellung von dendritischen Zellen aus CD14+ Monocyten In vitro production of dendritic cells from CD14 + monocytes
06/14/2007DE102005059751A1 Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie Aqueous dispersion of superparamagnetic single-domain particles, their preparation and use for the diagnosis and therapy
06/14/2007DE102005059750A1 Use of tetraorganosilicon compound having cell proliferation inhibitory activity, e.g. as an immunstimulator to treat viral-, bacterial- and/or tumor diseases, anemia, arteriosclerosis, arthritis, asthma, autoimmune disease, and cirrhosis
06/14/2007DE10103565B4 Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus Compositions comprising a ruthenium (III) complex and a heterocycle
06/14/2007CA2640836A1 Method for generating dendritic cells employing decreased temperature
06/14/2007CA2638902A1 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
06/14/2007CA2633166A1 Treatment of barrett's esophagus
06/14/2007CA2632552A1 Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
06/14/2007CA2632512A1 Bicyclic compounds with kinase inhibitory activity
06/14/2007CA2632419A1 Genetically recombinant anti-perp antibody
06/14/2007CA2632417A1 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
06/14/2007CA2632384A1 Methods of preparing a vegf-r inhibitor
06/14/2007CA2632217A1 Pyridiazinone derivatives for the treatment of tumours
06/14/2007CA2631291A1 Antiproliferative pyrimidyl, fused pyrimidyl and pyridyl hydrazones
06/14/2007CA2630904A1 Compositions and methods for therapy and diagnosis of cancer
06/14/2007CA2630784A1 Process for the preparation of purified crystalline cci-779
06/14/2007CA2630553A1 Estrogen cancer therapy
06/14/2007CA2630483A1 Human monoclonal antibodies to o8e
06/14/2007CA2630468A1 Medicinal drug
06/14/2007CA2629743A1 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
06/14/2007CA2629132A1 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
06/14/2007CA2628756A1 Interleukin-11 compositions and methods of use
06/13/2007EP1795596A1 Composition and methods for therapy and diagnosis of cancer
06/13/2007EP1795539A1 Cell penetrating peptides for intracellular delivery of molecules
06/13/2007EP1795206A1 Drug for treating or preventing hcv infection
06/13/2007EP1795203A2 Fhit proteins and nucleic acids and methods based thereon
06/13/2007EP1795198A1 Treatment of Barret's esophagus
06/13/2007EP1795192A2 1-Substituted imidazole derivatives as nos inhibitors
06/13/2007EP1795182A1 Liposome improving intracellular drug delivery
1 ... 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 ... 2211